Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues

被引:46
作者
Fan, YD
Liu, ZX
Fang, XL
Ge, Z
Ge, N
Jia, Y
Sun, P
Lou, FL
Björkholm, M
Gruber, A
Ekman, P
Xu, DW
机构
[1] Karolinska Univ Hosp, Div Urol, Dept Surg, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept OncolPathol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Div Hematol, Dept Med, Stockholm, Sweden
[4] Qilu Hosp, Dept Urol, Jinan, Peoples R China
[5] Inst Urol, Jinan, Peoples R China
[6] Shandong Univ, Sch Nursing, Aging & Hlth Ctr, Jinan 250100, Peoples R China
关键词
D O I
10.1158/1078-0432.CCR-05-0099
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of telomerase, a key event during immortalization and malignant transformation, requires expression of the telomerase reverse transcriptase (hTERT). Consistently, lack of telomerase activity and hTERTexpression occurs in most normal human somatic cells. However, it has been observed that both normal and cancerous renal tissues express hTERTwhereas only the latter exhibits telomerase activity. The mechanism underlying the dissociation between hTERT expression and telomerase activity is unclear. In the present study, we examined telomerase activity and alternative splicing of hTERT transcripts in renal cell carcinoma (RCC) specimens and adjacent normal tissues from 33 patients with RCC.Telomerase activity was detectable in 27 of 33 (82%) RCC samples but none in their normal counterparts. Thirty-two of 33 tumors expressed overall hTERT mRNA and 27 of them contained full-length hTERT transcripts, all with telomerase activity. Although 42% (14 of 33) of normal renal samples expressed hTERT mRNA, none of them had full-length hTERT transcripts, coinciding with lack of telomerase activity. The presence of full-length hTERT mRNA and telomerase activity was significantly associated with c-MYC induction. In tumors, absence of full-length hTERT mRNA or telomerase activity defines a subgroup of nonmetastatic, early-stage RCCs. Taken together, telomerase repression in normal renal tissues is attributed to the absence of full-length hTERT transcripts, whereas telomerase activation is achieved via induction of or switch to expression of full-length hTERT mRNA during the oncogenic process of kidneys, and associated with aggressive RCCs.
引用
收藏
页码:4331 / 4337
页数:7
相关论文
共 42 条
[1]   Reconstitution of human telomerase activity in vitro [J].
Beattie, TL ;
Zhou, W ;
Robinson, MO ;
Harrington, L .
CURRENT BIOLOGY, 1998, 8 (03) :177-180
[2]   Switching and signaling at the telomere [J].
Blackburn, EH .
CELL, 2001, 106 (06) :661-673
[3]  
Cerezo A, 2002, J CELL SCI, V115, P1305
[4]   The hTERTα splice variant is a dominant negative inhibitor of telomerase activity [J].
Colgin, LM ;
Wilkinson, C ;
Englezou, A ;
Kilian, A ;
Robinson, MO ;
Reddel, RR .
NEOPLASIA, 2000, 2 (05) :426-432
[5]   Human telomerase and its regulation [J].
Cong, YS ;
Wright, WE ;
Shay, JW .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2002, 66 (03) :407-+
[6]   Reassessment of the 1997 TNM classification system for renal cell carcinoma - A 5-cm T1/T2 cutoff is a better predictor of clinical outcome [J].
Elmore, JM ;
Kadesky, KT ;
Koeneman, KS ;
Sagalowsky, AI .
CANCER, 2003, 98 (11) :2329-2334
[7]   Telomerase activity in human renal cell carcinoma [J].
Fujioka, T ;
Hasegawa, M ;
Suzuki, Y ;
Suzuki, T ;
Sugimura, J ;
Tanji, S ;
Koike, H .
INTERNATIONAL JOURNAL OF UROLOGY, 2000, 7 (01) :16-21
[8]   Transient induction of metallothionein isoform 3 (MT-3), c-fos, c-jun and c-myc in human proximal tubule cells exposed to cadmium [J].
Garrett, SH ;
Phillips, V ;
Somji, S ;
Sens, MA ;
Dutta, R ;
Park, S ;
Kim, D ;
Sens, DA .
TOXICOLOGY LETTERS, 2002, 126 (01) :69-80
[9]   Role of telomeres and telomerase in the pathogenesis of human cancer [J].
Hahn, WC .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) :2034-2043
[10]   CORRELATING TELOMERASE ACTIVITY LEVELS WITH HUMAN NEUROBLASTOMA OUTCOMES [J].
HIYAMA, E ;
HIYAMA, K ;
YOKOYAMA, T ;
MATSUURA, Y ;
PIATYSZEK, MA ;
SHAY, JW .
NATURE MEDICINE, 1995, 1 (03) :249-255